Showing 3811-3820 of 7373 results for "".
- Merz On The Move: Reflections On Fiscal Year 2015/16https://practicaldermatology.com/news/merz-on-the-move-reflections-on-fiscal-year-201516/2458365/Merz Pharma’s core business has grown by 8.9 percent from EUR 809.8 million to EUR 881.9 million in fiscal 2015/16, the company reports. The company’s total revenue of EUR 1,092.9 million has declined by 5.5 percent compared to previous year
- Office Job, Stress And Diet May Increase Risk of Adult Acnehttps://practicaldermatology.com/news/office-job-stress-diet-may-increase-risk-of-adult-acne/2458370/Lifestyle factors -- including stress -- may play a role in adult acne development, a new study suggests. Researchers in Italy compared 248 women diagnosed with adult acne to 270 women without acne. They found that adult acne was associated with a personal history of acne in adolesce
- New from Topix: Replenix® Pure Hydration Moisture Balmhttps://practicaldermatology.com/news/new-from-topix-replenix-pure-hydration-moisture-balm/2458368/The latest from Topix Pharmaceuticals, Inc., Replenix® Pure Hydration Moisture Balm, targets dry and aging skin. Various molecular weights of Hyaluronic Acid draw moisture into the skin and work with Yucca Glauca
- Derms Commonly Misdiagnose Fungal Skin Infectionshttps://practicaldermatology.com/news/fungal-skin-infections-commonly-misdiagnosed/2458372/Fungal skin infections may be commonly misdiagnosed, according to a survey in the Journal of the American Academy of Dermatology. George Washington University (GW) dermatologist Adam Friedman, MD and colleag
- Two New Studies Suggest BPX-01 Topical Minocycline May Hold Advantageshttps://practicaldermatology.com/news/two-new-studies-suggest-bpx-01-topical-minocycline-may-hold-advantages/2458376/Taken together, two new studies suggest that BioPharmX Corp.’s BPX-01 topical minocycline may have a favorable pharmacokinetic advantage compared with oral minocycline for the treatment of acne vulgaris. The research was at the Skin Disease Edu
- Mederma To Offer Products for Healthier Hair, Skin and Nailshttps://practicaldermatology.com/news/mederma-to-offer-products-for-healthier-hair-skin-and-nails/2458377/It’s not just scar and stretch mark reduction for Mederma anymore. Perhaps best known for such legacy products as scar gel and cream and stretch mark therapy, Mederma is now rolling out three new product lines for healthier hair, skin and nails.
- Most Indoor Tanning Salons in Texas Do Comply with Tanning Bans for Minorshttps://practicaldermatology.com/news/most-indoor-tanning-salons-in-texas-do-comply-with-tanning-bans-for-minors/2458378/Most indoor tanning salons comply with Texas’ tanning ban for those under 18, new research suggests. When female employees of a mystery shopping firm called posing as 17-year-olds interested in tanning, 81 percent of indoor tanning facilities complied with the Texas ban on indoor ta
- Precision Medicine in Action: Clinical Features May Help ID High Risk Melanoma Patientshttps://practicaldermatology.com/news/precision-medicine-in-action-clinical-featires-may-help-id-high-risk-melanoma-patients/2458379/Zeroing in on an individual’s risk factors for melanoma can help identify high-risk patients who may benefit from increased surveillance, new research suggests. Caroline G. Watts, M.P.H., of the University of Sydney, Australia, and coauthors examined clinical features associated wit
- Can IL-33 Blockade Ease Severe Poison Ivy Itch? Mouse Study Says Maybehttps://practicaldermatology.com/news/can-il-33-blockers-ease-severe-poison-ivy-itch/2458382/Blocking interleukin 33 (IL-33) may put the brakes on the uncontrollable itch caused by poison ivy, poison sumac, poison oak and even mango trees, according to a mouse study conducted by scientists at Duke Health in Durham, NC, and Zhejiang Chinese Medical University in China. The r
- FDA Approves Expanded Use Of Enbrel To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-expanded-use-of-enbrel-to-treat-children-with-chronic-moderate-to-severe-plaque-psoriasis/2458383/The FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Amgen's Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. The approval is based